ZK 200775 is an antagonist at the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and had earned attention a possible neuroprotective agent in cerebral ischemia. Probands receiving the agent within a stroke therapy related Phase I trial reported on an alteration of visual perception. In this trial, the effects of ZK 200775 on the visual system will be analyzed in detail. In a randomised, placebo-controlled, double-blind study eyes and vision will be examined before and after the intravenous administration of ZK 200775. The following methods will be applied: clinical examination, visual acuity, ophthalmoscopy, colour vision, rod absolute threshold, central visual field, pattern-reversal visual evoked potentials (pVEP), ON-OFF and full-field electroretinogram (ERG).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
18
Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
Intravenous infusion of sodium chloride over a period of 4 hours.
Charité Unviversitätsmedizin Berlin, Augenklinik Campus Virchow-Klinikum
Berlin, State of Berlin, Germany
Visual acuity
Color vision (Panel D-15 test), dark vision (adaptometer), full-field electroretinogram
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.